Alexion data at 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) showcase impact of C5 inhibition in NMOSD
Real-world and clinical data in NMOSD, including late-breaker presentation, will illustrate safety and efficacy of Ultomiris and Soliris and help inform clinical practice. Alexion, AstraZeneca Rare Disease, will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS), taking place 11 to 13 October 2023. Real-world and clinical data will provide further evidence to support the established safety and efficacy of Ultomiris (